Alnylam Pharmaceuticals Stock Investor Sentiment
| ALNY Stock | USD 283.34 29.79 11.75% |
Slightly above 66 percent of all Alnylam Pharmaceuticals' investors are curious in acquiring. The analysis of the overall investor sentiment regarding Alnylam Pharmaceuticals suggests that a large number of traders are confidant. Alnylam Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Alnylam Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Comfort Level 66
Interested
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Alnylam Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Alnylam Pharmaceuticals.
News SentimentBullish | Hype SentimentBullish | Insider SentimentDisposing |
Alnylam Historical Sentiment
Although Alnylam Pharmaceuticals' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Alnylam, such as negative comments on social media and news outlets, may cause fear in the market and push Alnylam Pharmaceuticals' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Alnylam.
Alnylam |
Alnylam Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Alnylam Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Alnylam Pharmaceuticals Historical Investor Sentiment
Investor biases related to Alnylam Pharmaceuticals' public news can be used to forecast risks associated with an investment in Alnylam. The trend in average sentiment can be used to explain how an investor holding Alnylam can time the market purely based on public headlines and social activities around Alnylam Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Alnylam Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Alnylam Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Alnylam Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Alnylam Pharmaceuticals.
Far too much social signal, news, headlines, and media speculation about Alnylam Pharmaceuticals that are available to investors today. That information is available publicly through Alnylam media outlets and privately through word of mouth or via Alnylam internal channels. However, regardless of the origin, that massive amount of Alnylam data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Alnylam Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Alnylam Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Alnylam Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Alnylam Pharmaceuticals alpha.
Alnylam Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 11250 shares by Sharp Phillip A of Alnylam Pharmaceuticals at 131.21 subject to Rule 16b-3 | 01/23/2025 |
2 | Disposition of 6667 shares by Kevin Fitzgerald of Alnylam Pharmaceuticals at 97.72 subject to Rule 16b-3 | 01/24/2025 |
3 | Disposition of 25000 shares by Garg Pushkal of Alnylam Pharmaceuticals at 88.95 subject to Rule 16b-3 | 01/27/2025 |
4 | GILD Stock Up on Q4 Earnings and Sales Beat Upbeat 25 Guidance | 02/12/2025 |
5 | Global Transmucosal Drugs Market to Reach USD 28 Billion by 2032 DelveInsight | 02/18/2025 |
6 | Global Oligonucleotide Synthesis Market to Cross USD 7 Billion by 2032 DelveInsight | 02/25/2025 |
7 | Disposition of 120 shares by Garg Pushkal of Alnylam Pharmaceuticals at 242.7 subject to Rule 16b-3 | 03/04/2025 |
8 | Grove AI Awarded the SCOPE Participant Engagement Award for Its AI-Powered Digital Staff and Platform for Clinical Trial Operations | 03/05/2025 |
9 | High Growth Tech Stocks Leading The US Market | 03/06/2025 |
10 | 3 High Growth Tech Stocks To Watch In The US Market | 03/10/2025 |
11 | Disposition of 1908 shares by Poulton Jeffrey V. of Alnylam Pharmaceuticals subject to Rule 16b-3 | 03/12/2025 |
12 | StockNews.com Upgrades Alnylam Pharmaceuticals to Buy | 03/14/2025 |
13 | Alnylam Pharmaceuticals, Inc. Short Interest Update | 03/18/2025 |
14 | Disposition of 440 shares by Greenstreet Yvonne of Alnylam Pharmaceuticals at 243.23 subject to Rule 16b-3 | 03/20/2025 |
Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.